Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jikui Shen

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 16, 2013
Sustained delivery of a HIF-1 antagonist for ocular neovascularizationTakeshi Iwase, Jie Fu, Tsunehiko Yoshida, et al.
Nature Communications|February 6, 2020
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticlesHiroki Tsujinaka, Jie Fu, Jikui Shen, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 2, 2005
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitiveYuji Oshima, Sachiko Oshima, Hiroyuki Nambu, et al.
The Journal of Clinical Investigation|September 3, 2014
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculatureJikui Shen, Maike Frye, Bonnie L Lee, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 16, 2013
Sustained delivery of a HIF-1 antagonist for ocular neovascularizationTakeshi Iwase, Jie Fu, Tsunehiko Yoshida, et al.
Nature Communications|February 6, 2020
Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticlesHiroki Tsujinaka, Jie Fu, Jikui Shen, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 2, 2005
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitiveYuji Oshima, Sachiko Oshima, Hiroyuki Nambu, et al.
The Journal of Clinical Investigation|September 3, 2014
Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculatureJikui Shen, Maike Frye, Bonnie L Lee, et al.
Mabs|December 9, 2016
Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degenerationKun Ding, Lucia Eaton, Diana Bowley, et al.
Pageof 7